Metabolism of a New Bactericidal Antiseptic, OPB-2045, in Rats following Subcutaneous Administration
スポンサーリンク
概要
- 論文の詳細を見る
- 1998-08-28
著者
-
Odomi Masaaki
大塚製薬株式会社徳島研究所
-
KUDO Shoji
大塚製薬株式会社徳島研究所
-
UMEHARA Ken
大塚製薬株式会杜徳島研究所
-
MIYAMOTO Gohachiro
大塚製薬株式会杜徳島研究所
-
Miyamoto G
Otsuka Pharmaceutical Co. Ltd. Tokushima
関連論文
- Absorption and Excretion of OPB-2045 following a Single Oral Administration to Rats
- Absorption, Distribution and Excretion of OPB-2045 following a Single Subcutaneous Administration to Beagle Dogs
- Absorption, Distribution and Excretion of OPB-2045 following a Single Subcutaneous Administration to Rats
- Percutaneous Absorption and Tissue Distribution of 1- (3, 4-dichlorobenzyl) -5-octylbiguanide (OPB-2045) in Rats
- Distribution (Autoradiography) of a New Synthetic Antibacterial Agent OPB-2045 in Rats
- Leukopenia-Inducing Effect of a Combination of a New 5-Fluorouracil (5-FU)-Derived Drug, BOF-A2(Emitefur), with Other 5-FU-Derived Drugs or BV-araU(Sorivudine) in Rats
- Metabolism of a New Bactericidal Antiseptic, OPB-2045, in Rats following Subcutaneous Administration
- Pharmacokinetics of OPB-2045 in Rats : Systemic Exposure following Oral, Subcutaneous, and Intravenous Administration
- Metabolism of a New 1,4-dihydropyridine Calcium Antagonist, Pranidipine, by cDNA-expressed Human Cytochrome P450